Schlaich said the endothelin pathway has been previously “implicated in the pathogenesis of hypertension,” particularly in sodium and water retention; the endothelin A and B receptors exert their ...

Panelists discuss how the pathophysiology of pulmonary arterial hypertension involves complex mechanisms across multiple ...

Zibotentan is a novel once daily tablet and works by blocking the endothelin pathway. As prostate cancer advances, this pathway becomes uncontrolled, which then drives the spread of cancer growth.

Uptravi (selexipag) + ERA: Combining Uptravi (selexipag) and an ERA drug, such as Opsumit (macitentan), targets the ...

Sparsentan, developed by Travere Therapeutics, is an experimental drug that targets both the endothelin and angiotensin pathways involved in IgAN. The results of the PROTECT study showed that ...

The first, dual endothelin receptor antagonist aprocitentan, acts by targeting the endothelin pathway implicated in hypertension. It lowered systolic BP after 4 weeks in the phase III, placebo ...

In this study, the authors found stimuli other than endothelin also induced hypertrophy via the IP3-calcium-NFAT pathway. They showed that these stimuli, such as adrenalin (the fight or flight ...

After Johnson & Johnson last year changed its mind on its 2017 purchase of aprocitentan, the medicine's original maker has ushered the drug across the FDA finish line. The once-daily drug, branded ...

“Since the endothelin pathway was not yet tackled in these patients, we selected aprocitentan, an endothelin receptor antagonist with the ideal properties for use in this condition. We were ...

TRYVIO is the first oral anti-hypertensive therapy which works via a new therapeutic pathway to be approved in almost 40 years. Idorsia plans to make TRYVIO available to the millions of patients ...